This competitor is identified as one of the primary competitors in the peripheral intervention market, alongside others, and operates in the global medical technology marketplace characterized by rapid technological advancement and customer demands for price reductions.  **[856982_0000856982-25-000011_mmsi-20241231x10k.htm:15]** 

Teleflex Inc

This competitor is highlighted as a primary competitor in the peripheral intervention, cardiac intervention, and spine markets. It is one of the larger companies with extensive resources in the medical device industry.  **[856982_0000856982-25-000011_mmsi-20241231x10k.htm:15]** 

Medtronic PLC

This competitor is listed as a primary competitor in the peripheral intervention, cardiac intervention, and endoscopy markets. It is part of the competitive landscape in the global medical technology marketplace.  **[856982_0000856982-25-000011_mmsi-20241231x10k.htm:15]** 

Boston Scientific Corp

This competitor is identified as a primary competitor in the peripheral intervention, cardiac intervention, and oncology markets. It is noted for its involvement in various product lines.  **[856982_0000856982-25-000011_mmsi-20241231x10k.htm:15]** 

Becton Dickinson and Co

This competitor is mentioned as a primary competitor in the cardiac intervention market, competing in the global medical technology marketplace.  **[856982_0000856982-25-000011_mmsi-20241231x10k.htm:15]** 

Abbott Laboratories

This competitor is identified as a primary competitor in the cardiac intervention market, contributing to the competitive dynamics of the industry.  **[856982_0000856982-25-000011_mmsi-20241231x10k.htm:15]** 

Edwards Lifesciences Corp

This competitor is mentioned as a primary competitor in the spine market, competing in the global medical technology marketplace.  **[856982_0000856982-25-000011_mmsi-20241231x10k.htm:15]** 

Stryker Corp

This competitor is listed as a primary competitor in the spine market, operating as one of the larger companies in the medical device industry.  **[856982_0000856982-25-000011_mmsi-20241231x10k.htm:15]** 

Johnson & Johnson

This competitor is identified as a primary competitor in the oncology market, contributing to the competitive landscape in this segment.  **[856982_0000856982-25-000011_mmsi-20241231x10k.htm:15]** 

Component Name	Amount ($USD)	Payment Schedule	Additional Details
Base Salary	1,890,000	Effective January 1, 2024 (Annually)	Fixed annual salary
Stock Awards	7,132,948	As per grant vesting schedules in 2024	RSUs: 24,572 shares (fair value 1,880,000) and PSUs: 16,402 target shares (grant date fair value 7,132,948)
All Other Compensation	10,350	Paid during 2024 as applicable	Includes 401(k) matching contributions; Vacation Benefits not applicable
Termination Benefits (Involuntary Termination Without Cause or For Good Reason)	16,228,714	Triggered upon meeting termination conditions	Comprises: Discretionary Severance 3,780,000; Stock Option Vesting Acceleration 2,421,740; Stock Award Vesting Acceleration 9,969,824; Health Plan Coverage 57,150; Deferred Compensation not applicable
Termination Benefits (Change in Control)	22,371,432	Triggered upon a change in control event	Comprises: Salary and Bonus Continuation 9,347,843; Stock Option Vesting Acceleration 2,421,740; Stock Award Vesting Acceleration 10,513,017 (includes Target Cash Incentives for 2024, 2023, 2022); Health Plan Coverage 88,832; Deferred Compensation not applicable

Metric	Value
Performance Threshold	$510,300
Performance Target	$1,134,000
Performance Maximum	$1,871,100
Actual Performance Payout	118.90% of target
Vesting/Payment Schedule	Paid out in 2025 after the performance period
Conditions	Achievement of performance criteria set by the Compensation Committee
Bonus Modifier	Capped at 110% (modifier applied as per plan terms)

Fred P. Lampropoulos

Also at MERIT MEDICAL SYSTEMS

About

$MMSI Performance Under Fred P. Lampropoulos

Past Roles

Fixed Compensation

Performance Compensation

Performance Compensation Details